International immunopharmacology.Sep 2015;28(1):802-807
There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop, said senior author Ziyad Al-Aly, MD, a WashU Medicine clinical epidemiologist and chief of the Research and Development Service at the VA Saint Louis Health Care System
BPC-157 has been shown in preclinical research to accelerate tendon and ligament healing, reduce gut inflammation, promote nerve repair, stimulate new blood vessel formation, reduce systemic inflammation, and protect joint cartilage
FDA's evaluation concluded that the criteria weighed against placement on the list, citing inadequate physicochemical characterization, immunogenicity concerns from impurities and aggregates, lack of clinical effectiveness data for any approved use, and absence of published human exposure data for the proposed subcutaneous and topical routes
Benefits & Considerations Potential Benefits: Greater total fat loss Reduced hunger and cravings Possible metabolic improvements beyond semaglutide May help maintain results long-term Considerations: Not yet FDA-approved Side effects may overlap (nausea, constipation, fatigue) Long-term safety data still limited Why This Matters for the Future of Weight Management The combination of Retatrutide + Cagrilintide represents the next evolution of metabolic pharmacology, one that treats obesity like the complex, multi-hormonal disease it is